Preclinical studies in rodent models of ischemic stroke have established that that administration of Alb at high doses (25%, 2.5 g/kg, i.v.)decreases infarct volume, reduces brain swelling [7,26] and improves local cerebral perfusion in affected tissue [27] Moderate doses of Alb therapy (0.63 or 1.25 g/kg) also improve neurological function and reduce infarct volume and brain swelling, even when treatment is delayed up to 4 hours after onset of ischemia in rats [8]. This evidence concerns the gene ALB and ischemia.